67 results on '"R Andrew Seaton"'
Search Results
52. Extra-Pulmonary Tuberculosis
- Author
-
R. Andrew Seaton
- Subjects
Pathology ,medicine.medical_specialty ,Extra pulmonary tuberculosis ,Pulmonary tuberculosis ,business.industry ,medicine ,business ,Virology - Published
- 2008
53. Prevalence Surveys of Antimicrobial Use in Hospitals: Purpose, Practicalities, and Pitfalls
- Author
-
R. Andrew Seaton
- Subjects
medicine.medical_specialty ,Antimicrobial use ,business.industry ,Family medicine ,Medicine ,Prevalence survey ,business ,Antimicrobial ,Biotechnology - Abstract
Antimicrobials are widely used in hospitals for a broad range of conditions by a variety of specialists. Prescribing is largely empiric and is dependent on the recognition of clinical syndromes and the prescribers’ experience, including their own awareness of likely causative microbes, local resistance profiles and their knowledge of antimicrobial therapy. As the majority of prescribers work in system-based specialities, their interest and expertise in microbiology and antimicrobial therapy is variable.1 These factors may at least partly explain the observed variation and quality in prescribing practice.
- Published
- 2008
54. Treatment of skin and soft tissue infections with daptomycin: UK Experience
- Author
-
R. Andrew Seaton and JB Sarma
- Subjects
Microbiology (medical) ,medicine.medical_specialty ,Infectious Diseases ,business.industry ,Medicine ,Soft tissue ,Daptomycin ,business ,Surgery ,medicine.drug - Published
- 2011
55. Prior trimethoprim use and trimethoprim-resistant urinary tract infection: a nested case-control study with multivariate analysis for other risk factors
- Author
-
G. Phillips, R. Andrew Seaton, Peter Davey, Thomas M. MacDonald, and Douglas Steinke
- Subjects
Microbiology (medical) ,Male ,medicine.medical_specialty ,Anti-Infective Agents, Urinary ,Microbial Sensitivity Tests ,Drug Prescriptions ,Trimethoprim ,Cohort Studies ,Risk Factors ,Internal medicine ,Escherichia coli ,Medicine ,Humans ,Pharmacology (medical) ,Risk factor ,Antibacterial agent ,Pharmacology ,business.industry ,Trimethoprim Resistance ,Case-control study ,Odds ratio ,Middle Aged ,bacterial infections and mycoses ,Proteus ,Drug Utilization ,Infectious Diseases ,Case-Control Studies ,Immunology ,Nested case-control study ,Multivariate Analysis ,Urinary Tract Infections ,Female ,business ,medicine.drug ,Cohort study - Abstract
Trimethoprim resistance is increasingly prevalent in community-acquired urinary infections. The objective of this study was to evaluate the association between exposure to community-prescribed trimethoprim and other risk factors in subjects and subsequent trimethoprim-resistant urinary tract infection. The design was a nested case-control study using a record-linkage database. Study subjects submitted a urine sample to the Ninewells Hospital Laboratory between July 1993 and December 1995. Antibiotic exposure in subjects with trimethoprim-resistant isolates (cases) was compared with antibiotic exposure in subjects with trimethoprim-susceptible isolates (controls). Study subjects were drawn from the catchment area of a large teaching hospital in Tayside, Scotland. There were 13765 males and females aged 1-106 years who submitted their first urine sample for culture during the study period. After adjustment for significant risk factors and confounding variables, logistic regression analysis showed exposure to trimethoprim [odds ratio (OR) 4.35] or any antibiotic other than trimethoprim (OR 1.32) to be predictive of resistance. The growth of Proteus spp. (OR 115.14) and bacterial growth other than Escherichia coli and Proteus spp. (OR 2.83) were also predictor variables. Hospitalization in the previous 6 months was not independently associated with trimethoprim resistance. In conclusion, trimethoprim resistance was independently associated with exposure to trimethoprim and to antibiotics other than trimethoprim. Reduction in trimethoprim prescribing alone may not reduce the prevalence of trimethoprim resistance.
- Published
- 2001
56. Bio-hazards and drug reactions: A cautionary tale
- Author
-
S. Erica Peters and R. Andrew Seaton
- Subjects
Microbiology (medical) ,Infectious Diseases ,General Immunology and Microbiology ,General Medicine - Published
- 2005
57. Tick bite and early Lyme borreliosis
- Author
-
George Carle, R. Andrew Seaton, and Christopher J A Duncan
- Subjects
Male ,Lyme Disease ,Veterinary medicine ,medicine.medical_specialty ,Ixodes ricinus ,biology ,Transmission (medicine) ,Incidence (epidemiology) ,Insect Bites and Stings ,General Medicine ,Middle Aged ,Tick ,medicine.disease ,biology.organism_classification ,United Kingdom ,Lyme disease ,parasitic diseases ,Epidemiology ,medicine ,Humans ,Erythema migrans ,Ixodes ,Demography - Abstract
A 48 year old man removed two ticks attached to his leg while walking in the Scottish Highlands. A week later he develops a rash and consults you worried about Lyme disease. Epidemiology— Lyme borreliosis is the commonest tick-borne infection in the northern hemisphere. It is relatively uncommon in the UK overall (about 1200 cases in 2009), but marked geographical variation is observed. Risk is highest in rural forested areas and heathland such as the Highlands (incidence 56.35/100 000 in 2009-101), Lake District, and New Forest. Some 15–20% of infections are acquired in Europe or the US. There has been a steady rise in cases diagnosed in the UK over the past decade.2 3 Risk assessment— Ask about duration of hard bodied ( Ixodes ) tick attachment, with or without engorgement (fig 1⇓). Transmission of pathogenic Borrelia species is unlikely if ticks are attached for
- Published
- 2012
58. Treatment of osteoarticular infections with daptomycin, UK experience
- Author
-
Armando Gonzalez-Ruiz and R. Andrew Seaton
- Subjects
Microbiology (medical) ,Pediatrics ,medicine.medical_specialty ,Infectious Diseases ,business.industry ,medicine ,Daptomycin ,business ,Intensive care medicine ,medicine.drug - Published
- 2011
59. Clinical experience with daptomycin in the United Kingdom
- Author
-
Achyut Guleri, Jayanta B. Sarma, Armando Gonzalez-Ruiz, Angela Galloway, and R. Andrew Seaton
- Subjects
Microbiology (medical) ,medicine.medical_specialty ,Pediatrics ,Infectious Diseases ,business.industry ,Family medicine ,medicine ,Daptomycin ,business ,medicine.drug - Published
- 2011
60. Complicated skin and soft tissue infections: literature review of evidence for and experience with daptomycin
- Author
-
Beth White and R. Andrew Seaton
- Subjects
Pharmacology ,medicine.medical_specialty ,outpatient parenteral antibiotic therapy ,business.industry ,SSTI ,Parenteral antibiotic ,Soft tissue ,Lipopeptide ,Review ,MRSA ,OPAT ,Antimicrobial ,Surgery ,Oral agents ,chemistry.chemical_compound ,Infectious Diseases ,chemistry ,lipopeptide ,medicine ,Pharmacology (medical) ,Daptomycin ,Once daily ,Intensive care medicine ,business ,medicine.drug - Abstract
Skin and soft tissue infections (SSTIs) are the second most common infection encountered in hospitals. Management decisions have become increasingly complex due to the prevalence of resistant pathogens, the wide array of licensed antimicrobials and the availability of potent oral agents and of out-patient parenteral antibiotic therapy. Daptomycin is one of the newer therapeutic agents licensed for complex SSTI management. Rapid cidality, good soft tissue penetration, once daily IV bolus administration and activity against resistant Gram-positive infections make daptomycin an attractive option both in hospitalized and community treated patients. A comprehensive review of the evidence for and experience with daptomycin and its use in SSTIs is presented.
- Published
- 2011
61. Daptomycin in a complicated case of pneumococcal infection
- Author
-
R. Andrew Seaton and A MacConnachie
- Subjects
Microbiology (medical) ,Infectious Diseases ,business.industry ,Immunology ,Medicine ,Daptomycin ,business ,medicine.drug - Published
- 2007
62. Nurse-led management of uncomplicated cellulitis in the community: evaluation of a protocol incorporating intravenous ceftriaxone.
- Author
-
R. Andrew Seaton, E. Bell, Y. Gourlay, and L. Semple
- Subjects
CELLULITIS ,CONNECTIVE tissue diseases ,CELLULAR pathology ,ANTIBIOTICS - Abstract
Objectives and methods: A management protocol for specialist nurses was developed for ambulatory management of uncomplicated cellulitis requiring initial intravenous (iv) antibiotic therapy. Patients were all managed through an outpatient parenteral antibiotic therapy (OPAT) service. Those with cellulitis were compared pre- and post-intervention.Results: One hundred and fourteen patients were compared with 230 retrospective controls all managed through the OPAT service. Protocol management was associated with reduced duration of outpatient iv therapy from 4 to 3 days, P=0.02, and reduced need for physician review (100% to 19%). Outcomes, complications and readmissions were similar.Conclusions: Specialist nurse-led management is safe and effective in the management of uncomplicated cellulitis in the context of an OPAT service and reduces the need for regular medical review without compromising clinical care. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
63. Outpatient parenteral antimicrobial therapy: Recent developments and future prospects
- Author
-
M Estee, Török, Ann L N, Chapman, M P Albert, Lessing, Frances, Sanderson, and R Andrew, Seaton
- Subjects
Dosage Forms ,Ertapenem ,Aminoglycosides ,Anti-Infective Agents ,Daptomycin ,Ambulatory Care ,Lipoglycopeptides ,Humans ,Infusions, Parenteral ,Teicoplanin ,beta-Lactams ,Anti-Bacterial Agents - Abstract
Patients with serious infections requiring parenteral antimicrobial therapy are usually hospitalized for treatment. For certain conditions, however, administration of parenteral antibiotics outside the hospital setting may be safe, efficacious, convenient for patients and cost-beneficial. Outpatient parenteral antimicrobial therapy (OPAT) was developed in the US initially and its use has expanded globally during the past three decades. A wide variety of infections are amenable to treatment by OPAT. Once-daily agents such as ceftriaxone or teicoplanin and, more recently, antimicrobials such as ertapenem or daptomycin have been used for OPAT. The use of higher doses and less-frequent dosing of existing agents is being explored, and exciting new developments include the emergence of agents with broader-spectrum activity against drug-resistant organisms and the use of antifungal agents in the OPAT setting. Future prospects in OPAT include the use of more recently launched drugs such as telavancin, as well as drugs in development, including dalbavancin (Durata Therapeutics Inc) and omadacycline (PTK-0796; Novartis AG/PARATEK Pharmaceuticals Inc). This review outlines recent developments in, and future prospects for, the antimicrobial agents used in OPAT.
64. Methicillin-resistant Staphylococcus aureus (MRSA) in East Africa: red alert or red herring?
- Author
-
Frederick K. Wangai, Moses M. Masika, Marybeth C. Maritim, and R. Andrew Seaton
- Subjects
Methicillin-resistant Staphylococcus aureus ,Antimicrobial resistance ,VITEK ,Methicillin ,Cefoxitin ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background Methicillin-resistant Staphylococcus aureus (MRSA) is associated with significant morbidity and mortality and has resultant important economic and societal costs underscoring the need for accurate surveillance. In recent years, prevalence rates reported in East Africa have been inconsistent, sparking controversy and raising concern. Methods We described antimicrobial susceptibility patterns of Staphylococcus aureus isolates cultured from patients within the Internal Medicine department of the largest public healthcare facility in East and Central Africa- the Kenyatta National Hospital (KNH) in Nairobi, Kenya. Routine antimicrobial susceptibility data from non-duplicate Staphylococcus aureus isolates cultured between the years 2014–2016 from the medical wards in KNH were reviewed. Results Antimicrobial susceptibility data from a total of 187 Staphylococcus aureus isolates revealed an overall MRSA prevalence of 53.4%. Isolates remained highly susceptible to linezolid, tigecycline, teicoplanin and vancomycin. Conclusions The prevalence of MRSA was found to be much higher than that reported in private tertiary facilities in the same region. Careful interrogation of antimicrobial susceptibility results is important to uproot any red herrings and reserve genuine cause for alarm, as this has a critical bearing on health and economic outcomes for a population.
- Published
- 2019
- Full Text
- View/download PDF
65. Strategies to Improve Antimicrobial Utilization with a Special Focus on Developing Countries
- Author
-
Brian Godman, Abiodun Egwuenu, Mainul Haque, Oliver Ombeva Malande, Natalie Schellack, Santosh Kumar, Zikria Saleem, Jacqueline Sneddon, Iris Hoxha, Salequl Islam, Julius Mwita, Renata Cristina Rezende Macedo do Nascimento, Isabella Piassi Dias Godói, Loveline Lum Niba, Adefolarin A. Amu, Joseph Acolatse, Robert Incoom, Israel Abebrese Sefah, Sylvia Opanga, Amanj Kurdi, Ibrahim Chikowe, Felix Khuluza, Dan Kibuule, Olayinka O. Ogunleye, Adesola Olalekan, Vanda Markovic-Pekovic, Johanna C. Meyer, Abubakr Alfadl, Thuy Nguyen Thi Phuong, Aubrey C. Kalungia, Stephen Campbell, Alice Pisana, Janney Wale, and R. Andrew Seaton
- Subjects
antimicrobials ,antimicrobial stewardship programs ,antimicrobial resistance ,healthcare-associated infections ,COVID-19 ,lower- and middle-income countries ,Science - Abstract
Antimicrobial resistance (AMR) is a high priority across countries as it increases morbidity, mortality and costs. Concerns with AMR have resulted in multiple initiatives internationally, nationally and regionally to enhance appropriate antibiotic utilization across sectors to reduce AMR, with the overuse of antibiotics exacerbated by the COVID-19 pandemic. Effectively tackling AMR is crucial for all countries. Principally a narrative review of ongoing activities across sectors was undertaken to improve antimicrobial use and address issues with vaccines including COVID-19. Point prevalence surveys have been successful in hospitals to identify areas for quality improvement programs, principally centering on antimicrobial stewardship programs. These include reducing prolonged antibiotic use to prevent surgical site infections. Multiple activities centering on education have been successful in reducing inappropriate prescribing and dispensing of antimicrobials in ambulatory care for essentially viral infections such as acute respiratory infections. It is imperative to develop new quality indicators for ambulatory care given current concerns, and instigate programs with clear public health messaging to reduce misinformation, essential for pandemics. Regular access to effective treatments is needed to reduce resistance to treatments for HIV, malaria and tuberculosis. Key stakeholder groups can instigate multiple initiatives to reduce AMR. These need to be followed up.
- Published
- 2021
- Full Text
- View/download PDF
66. Outpatient parenteral antimicrobial therapy (OPAT) in the UK: findings from the BSAC National Outcomes Registry (2015-19).
- Author
-
Gilchrist M, Barr D, Drummond F, Muir A, Williams J, Scriven J, Snape S, Hemsley C, Durojaiye CO, Patel S, and Andrew Seaton R
- Subjects
- Adult, Ambulatory Care, Anti-Bacterial Agents adverse effects, Child, Humans, Infusions, Parenteral, Registries, Treatment Outcome, United Kingdom, Anti-Infective Agents, Outpatients
- Abstract
Background: Reporting of outpatient parenteral antimicrobial therapy (OPAT) outcomes with national benchmarking is key to informing service development and supporting quality improvement., Objectives: To analyse and report on data collected by the BSAC OPAT National Outcomes Registry from 2015 to 2019., Methods: Quarterly data to 2020 was extracted from the BSAC National Outcomes Registry and analysed., Results: 57 organizations submitted data on 27 841 patient episodes and 442 280 OPAT treatment days. A diverse range of infections and antimicrobials were reported with a mean OPAT treatment duration of 16.7 days (adults) and 7.7 days (paediatrics). In adults, the top five conditions treated were skin and soft tissue (27.6%), bronchiectasis (11.4%), urinary tract infections (7.6%), and diabetic foot infections (5.5%). Ceftriaxone followed by teicoplanin, ertapenem and piperacillin/tazobactam were the most-used antimicrobials. A median of 1.4 vascular-device-related complications were observed per 1000 OPAT treatment days (range 0.11 to 10.4) with device infections in 0.3 per 1000 OPAT days (range 0.1 to 1.7). Other adverse events (rash, blood dyscrasias, antibiotic-associated diarrhoea) were observed in a median of 1.9 per 1000 OPAT days. OPAT infection outcome (cured/improved) was 92.4% and OPAT outcome (success/partial success) was 90.7%., Conclusions: This report demonstrates the safety, breadth, and complexity of modern UK OPAT practice. Future analyses of OPAT data should focus on infection- and service-specific quality indicators. OPAT registries remain central to planning and assessing safe, effective, and efficient delivery of patient-centred care and should be an important focus for UK and global OPAT practice., (© The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
67. EFNS guideline on the management of community-acquired bacterial meningitis: report of an EFNS Task Force on acute bacterial meningitis in older children and adults.
- Author
-
Chaudhuri A, Martinez-Martin P, Kennedy PG, Andrew Seaton R, Portegies P, Bojar M, and Steiner I
- Subjects
- Adolescent, Adult, Advisory Committees, Child, Humans, Community-Acquired Infections diagnosis, Community-Acquired Infections therapy, Meningitis, Bacterial diagnosis, Meningitis, Bacterial therapy
- Abstract
Acute bacterial meningitis (ABM) is a potentially life-threatening neurological emergency. An agreed protocol for early, evidence-based and effective management of community-acquired ABM is essential for best possible outcome. A literature search of peer-reviewed articles on ABM was used to collect data on the management of ABM in older children and adults. Based on the strength of published evidence, a consensus guideline was developed for initial management, investigations, antibiotics and supportive therapy of community-acquired ABM. Patients with ABM should be rapidly hospitalized and assessed for consideration of lumbar puncture (LP) if clinically safe. Ideally, patients should have fast-track brain imaging before LP, but initiation of antibiotic therapy should not be delayed beyond 3 h after first contact of patient with health service. In every case, blood sample must be sent for culture before initiating antibiotic therapy. Laboratory examination of cerebrospinal fluid is the most definitive investigation for ABM and whenever possible, the choice of antibiotics, and the duration of therapy, should be guided by the microbiological diagnosis. Parenteral therapy with a third-generation cephalosporin is the initial antibiotics of choice in the absence of penicillin allergy and bacterial resistance; amoxicillin should be used in addition if meningitis because of Listeria monocytogenes is suspected. Vancomycin is the preferred antibiotic for penicillin-resistant pneumococcal meningitis. Dexamethasone should be administered both in adults and in children with or shortly before the first dose of antibiotic in suspected cases of Streptococcus pneumoniae and H. Influenzae meningitis. In patients presenting with rapidly evolving petechial skin rash, antibiotic therapy must be initiated immediately on suspicion of Neisseria meningitidis infection with parenteral benzyl penicillin in the absence of known history of penicillin allergy.
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.